<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36251040</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1262</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of colorectal disease</Title><ISOAbbreviation>Int J Colorectal Dis</ISOAbbreviation></Journal><ArticleTitle>Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs.</ArticleTitle><Pagination><StartPage>2263</StartPage><EndPage>2276</EndPage><MedlinePgn>2263-2276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00384-022-04261-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Accumulating evidence showed that probiotics therapy might be effective in treating diarrhea-predominant irritable bowel syndrome (IBS-D). This study aimed to evaluate the effectiveness and safety of probiotics therapy for the treatment of IBS-D.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a comprehensive literature search in eight electronic databases, and gray literature from inception to August 4, 2021. Randomized controlled trials (RCTs) of probiotics therapy for the treatment of IBS-D were included and the quality was assessed using the risk of bias tool recommended by the Cochrane Handbook version 5.1.0. RevMan 5.4 software was used to perform the meta-analysis on the outcomes of IBS-D symptoms, abdominal pain, quality of life, and abdominal distension. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ten RCTs evaluating 943 patients were identified. Only one study had unclear risk of bias, while nine studies had a high risk of bias. The meta-analysis results showed that, compared to the placebo, probiotics therapy significantly decreased the score of IBS-D symptoms (SMD&#x2009;=&#x2009;&#x2009;-&#x2009;0.55, 95% CI: [-&#x2009;0.83,&#x2009;-&#x2009;0.27], P&#x2009;&lt;&#x2009;0.05), abdominal pain (SMD&#x2009;=&#x2009;&#x2009;-&#x2009;0.43, 95% CI: [-&#x2009;0.57,&#x2009;-&#x2009;0.29], P&#x2009;&lt;&#x2009;0.05), and abdominal distension (SMD&#x2009;=&#x2009;&#x2009;-&#x2009;0.45, 95%CI: [-&#x2009;0.81,&#x2009;-&#x2009;0.09], P&#x2009;&lt;&#x2009;0.05). There was no statistical difference in the quality of life. However, all the certainty of evidence was very low.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Very low certainty evidence showed that probiotics might be an effective treatment for improving the IBS-D symptoms, abdominal pain, and abdominal distension, in adult IBS-D patients. However, these conclusions should be supported by high-quality evidence.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research and Education Department, Shaanxi Provincial Rehabilitation Hospital, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Fangfen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>First Hospital of Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Kangle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gansu Provincial Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>E</LastName><ForeName>Fenfen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chaoqun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kehu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China. kehuyangebm2006@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China. kehuyangebm2006@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China. kehuyangebm2006@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Evidence-Based Social Science Research Center &amp; Health Technology Assessment Center, School of Public Health, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China. lixiuxia@lzu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China. lixiuxia@lzu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China. lixiuxia@lzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82004203</GrantID><Agency>the National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>lzujbky-2021-ct06, lzujbky-2021-kb22</GrantID><Agency>the Fundamental Research Funds for the Central Universities</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int J Colorectal Dis</MedlineTA><NlmUniqueID>8607899</NlmUniqueID><ISSNLinking>0179-1958</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diarrhea&#x2010;predominant irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Randomized controlled trials</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>17</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36251040</ArticleId><ArticleId IdType="doi">10.1007/s00384-022-04261-0</ArticleId><ArticleId IdType="pii">10.1007/s00384-022-04261-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wald A, Talley N and Grover S (2014) Clinical manifestations and diagnosis of irritable bowel syndrome in adults. UpToDate, Waltham, MA. (Accessed on 01 Nov 2016)</Citation></Reference><Reference><Citation>Mearin F, Lacy B, Chang L (2016) Rome IV: the functional bowel disorders. Gastroenterology 150:1393&#x2013;1407</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Health NIf and Excellence C (2017) Irritable bowel syndrome in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE)</Citation></Reference><Reference><Citation>Douglas A, Drossman et al (2016) Rome IV&#x2013;functional GI disorders: disorders of gut-brain interaction. Gastroenterology 150:1257&#x2013;1261</Citation></Reference><Reference><Citation>Cash BD, Lacy BE, Schoenfeld PS et al (2017) Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Official J Am College Gastroenterol | ACG 112</Citation></Reference><Reference><Citation>Yu TW, Lim HY, Tai D et al (2012) The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol 12:104</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-12-104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nellesen D, Yee K, Chawla A et al (2013) A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Managed Care Pharm JMCP 19:755&#x2013;674</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2013.19.9.755</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C, West J, Card T (2014) Review article: the economic impact of the irritable bowel syndrome. Alimentary Pharmacol Ther 40</Citation></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol</Citation></Reference><Reference><Citation>Guilarte M, Santos J, Torres ID et al (2007) Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56:203&#x2013;209</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2006.100594</ArticleId><ArticleId IdType="pubmed">17005763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes PA, Fraher MH, Quigley E (2014) Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol 10:164&#x2013;174</Citation></Reference><Reference><Citation>Camilleri M, Talley NJ, Travis AC (2000) Alosetron hydrochloride (Lotronex) for irritable bowel syndrome. Med Lett Drugs Ther 42:53&#x2013;54</Citation></Reference><Reference><Citation>IBS ACoGTFo (2009) Corrigendum: an evidence-based position statement on the management of irritable bowel syndrome. Official J Am College Gastroenterol | ACG 104</Citation></Reference><Reference><Citation>Vahedi H, Merat S, Momtahen S et al (2010) Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacol Ther 27</Citation></Reference><Reference><Citation>Ford AC, Lacy BE, Talley NJ (2017) Irritable bowel syndrome &#x2013; NEJM</Citation></Reference><Reference><Citation>Houte K, Colomier E, Schol J et al (2020) Recent advances in diagnosis and management of irritable bowel syndrome. Curr Opin Psychiatry. Publish Ahead of Print</Citation></Reference><Reference><Citation>Maharaul MS, Rathod CC, Agrawal VM et al (2015) Probiotics for diarrhoea &#x2013; predominant irritable bowel syndrome. Int J Res Med 4:68&#x2013;70</Citation></Reference><Reference><Citation>Abbas Z, Yakoob J, Jafri W et al (2014) Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 26</Citation></Reference><Reference><Citation>Skrzyd&#x142;o-Radoma&#x144;ska B, Prozorow-Kr&#xf3;l B, Cicho&#x17c;-Lach H et al (2020) The effectiveness of synbiotic preparation containing Lactobacillus and Bifidobacterium probiotic strains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome&#x2013;a randomized double-blind, placebo-controlled study. Nutrients 12:1999</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="pmc">7400954</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang X, Xiong L, Li L et al (2016) Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta&#x2010;analysis. J Gastroenterol Hepatol</Citation></Reference><Reference><Citation>Bhattarai Y, Muniz Pedrogo DA, Kashyap PC (2017) Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointestinal Liver Physiol 312:G52&#x2013;G62</Citation></Reference><Reference><Citation>Belgin D, Facey B, Dogan EI et al (2018) Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome. FEMS Microbiol Lett 22</Citation></Reference><Reference><Citation>Rolfe RD (2000) The role of probiotic cultures in the control of gastrointestinal health. J Nutr 130:396S</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/130.2.396S</ArticleId><ArticleId IdType="pubmed">10721914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioramonti J, Theodorou V et al (2003) Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 17:711&#x2013;724</Citation></Reference><Reference><Citation>Cha BK, Jung SM, Chang HC et al (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 46:220&#x2013;227</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31823712b1</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JC, Chan AO, Chan YW et al (2017) The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements. Hong Kong Med J Xianggang yi xue za zhi 23:641</Citation></Reference><Reference><Citation>Song KH, Hye-Kyung J, Jin KH et al (2018) Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil 24:197&#x2013;215</Citation></Reference><Reference><Citation>Study Group of Functional Gastrointestinal Disorders SGoGM (2020) Chinese Society of Gastroenterology, Chinese Medicine Association. Chinese expert consensus of irritable bowel syndrome in 2020. Chinese J Gastroenterol 40:16</Citation></Reference><Reference><Citation>Fukudo S, Okumura T, Inamori M et al (2021) Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 56:193&#x2013;217</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId><ArticleId IdType="pmc">7932982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Li Y-Q, Zuo XL et al (2008) Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacol Ther 28:994&#x2013;1002</Citation></Reference><Reference><Citation>Sun Y-Y, Li M, Li Y-Y et al (2018) The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep 8:1&#x2013;11</Citation></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE et al (2018) Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 48:1044&#x2013;1060</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Ford AC, Talley NJ et al (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325&#x2013;332</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2008.167270</ArticleId><ArticleId IdType="pubmed">19091823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li L, Guo C et al (2016) Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 16</Citation></Reference><Reference><Citation>Francavilla R, Piccolo M, Francavilla A et al (2019) Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol 53:e117</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000001023</ArticleId><ArticleId IdType="pubmed">29688915</ArticleId><ArticleId IdType="pmc">6382041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JR, Kong CF, Qu XK et al (2019) Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Saudi J Gastroenterol 26</Citation></Reference><Reference><Citation>Li B, Liang L, Deng H et al (2020) Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 11</Citation></Reference><Reference><Citation>Skrzyd&#x142;o-Radoma&#x144;ska B, Prozorow-Kr&#xf3;l B, Cicho&#x17c;-Lach H et al (2021) The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study. Nutrients 13:756</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030756</ArticleId><ArticleId IdType="pubmed">33652763</ArticleId><ArticleId IdType="pmc">7996889</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth GF, Thompson WG, Chey WD et al (2006) Functional bowel disorders. Gastroenterology 130:1480&#x2013;1491</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.061</ArticleId><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao WW, Jiang H, Tao XM et al (2016) Effects of acupuncture, Tuina, Tai Chi, Qigong, and traditional Chinese medicine five-element music therapy on symptom management and quality of life for cancer patients: a meta-analysis. J Pain Symp Manage 728</Citation></Reference><Reference><Citation>Yao X, Florez ID, Zhang P et al (2020) Clinical research methods for treatment, diagnosis, prognosis, etiology, screening, and prevention: a narrative review. J Evid Based Med 13:130&#x2013;136</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jebm.12384</ArticleId><ArticleId IdType="pubmed">32445266</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383&#x2013;394</Citation></Reference><Reference><Citation>Bro&#x17c;ek J, Akl EA, Alonso&#x2010;Coello P et al (2009) Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 64:669&#x2013;677</Citation></Reference><Reference><Citation>Dersimonian R, Nan L (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, Thompson SG, Decks JJ et al (2003) Measuring inconsistency in meta-analyses. British Med J 327:557&#x2013;560</Citation></Reference><Reference><Citation>Asha MZ, Khalil S (2020) Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Sultan Qaboos Univ Med J 20:13</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2020.20.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Mu Z, Xie J et al (2019) Effectiveness and safety of Chinese herbal medicine Xiaoyao San for the treatment of insomnia: protocol for a systematic review and meta-analysis. Medicine 98</Citation></Reference><Reference><Citation>Kim HJ et al (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacol Ther 17:895&#x2013;904</Citation></Reference><Reference><Citation>Ishaque MS, Khosruzzaman SM, Ahmed DS et al (2018) A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult) in the management of diarrhea predominant irritable bowel syndrome. Meditsinskiy sovet Med Council 98&#x2013;108</Citation></Reference><Reference><Citation>Skrzydo-Radoma&#x144;ska B, Prozorow-Kr&#xf3;l B, Cicho-Lach H et al (2021) The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study. Nutrients 13</Citation></Reference><Reference><Citation>Michail S, Kenche H (2011) Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL# 3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins 3:1&#x2013;7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-010-9059-y</ArticleId><ArticleId IdType="pubmed">22247743</ArticleId><ArticleId IdType="pmc">3255476</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CH, Jo SY, Park HJ et al (2011) A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 45:679&#x2013;683</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HC, Sun YJ, Park HJ et al (2011) A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 45:679&#x2013;683</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm SM, Brubaker CM, Varcak EA et al (2012) Effectiveness of probiotics in the treatment of irritable bowel syndrome. Pharmacotherapy 28</Citation></Reference><Reference><Citation>Yong W, Jl B, Ql B et al (2020) The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials. Int J Surg 79:111&#x2013;119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2020.04.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha MZ, Khalil S (2020) Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome. SQU J Sci Res Med Sci 20</Citation></Reference><Reference><Citation>Elfghi M, Jordan F, Sultan S et al (2020) Study within a trial protocol: same&#x2010;day consent vs. delayed consent in a randomized trial. J Evidence Based Med 13:246&#x2013;248</Citation></Reference><Reference><Citation>Yao L, Sun R, Chen Y-L et al (2016) The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol 74:73&#x2013;79</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2016.01.003</ArticleId><ArticleId IdType="pubmed">26780259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Zhang J, Ge L et al (2017) The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol 85:50&#x2013;58</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2016.12.004</ArticleId><ArticleId IdType="pubmed">28063911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge L, Tian J-H, Li Y-N et al (2018) Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study can China master the guideline challenge? J Clin Epidemiol 93:45&#x2013;55</Citation></Reference><Reference><Citation>Xiu-xia L, Ya Z, Yao-long C et al (2015) The reporting characteristics and methodological quality of Cochrane reviews about health policy research. Health Policy 119:503&#x2013;510</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2014.09.002</ArticleId><ArticleId IdType="pubmed">25260911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Gao W, Punja S et al (2016) Reporting quality of N-of-1 trials published between 1985 and 2013: a systematic review. J Clin Epidemiol 76:57&#x2013;64</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.11.016</ArticleId><ArticleId IdType="pubmed">26769257</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Cao L, Zhang Z et al (2021) Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping. J Clin Epidemiol</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>